ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)
Latest Information Update: 04 Nov 2024
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Favipiravir (Primary) ; Laninamivir (Primary) ; Molnupiravir (Primary) ; Oseltamivir (Primary) ; Peramivir (Primary) ; Zanamivir (Primary) ; Antipyretics
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms AD ASTRA
Most Recent Events
- 03 Jun 2024 Number of treatment arms are increased from 8 to 11 by the addition of 3 experimental drug combination arms.
- 03 Jun 2024 Planned number of patients changed from 250 to 3000.
- 03 Jun 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2027.